{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:04:55Z","timestamp":1788177895159,"version":"build-2803163510"},"reference-count":36,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2022,6,14]]},"abstract":"<jats:p>Background: Plasma phosphorylated-tau181 (p-tau181) is a promising biomarker for Alzheimer\u2019s disease (AD) and may offer utility for predicting preclinical disease. Objective: To evaluate the prospective association between plasma p-tau181 and amyloid-\u03b2 (A\u03b2) and tau-PET deposition in cognitively unimpaired individuals. Methods: Plasma p-tau181 levels were measured at baseline in 52 [48% women, mean 64.4 (SD 5.5) years] cognitively unimpaired Framingham Offspring cohort participants using samples stored between 2011\u20132014 who subsequently underwent 11C-Pittsburgh Compound-B (PiB)-PET and\/or 18F-Flortaucipir (FTP)-PET scans (n\u200a=\u200a18 with tau-PET) a mean of 6.8 (SD 0.6) years later. Our primary outcomes included A\u03b2-precuneus, A\u03b2-FLR (frontal, lateral, and retrosplenial cortices) and tau-global composite region PET deposition. Secondary outcomes included individual regional A\u03b2 and tau PET-deposition. P-tau181 was compared with plasma neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP) in predicting PET outcomes. Results: P-tau181 was associated with increased A\u03b2 deposition in the FLR (\u03b2\u00b1SE, 1.25\u00b10.30, p\u200a&lt;\u200a0.0001), precuneus (1.35\u00b10.29, p\u200a&lt;\u200a0.001), and other cortical regions. Plasma NFL (1.30\u00b10.49, p\u200a=\u200a0.01) and GFAP (1.46\u00b10.39, p\u200a&lt;\u200a0.001) were also associated with FLR A\u03b2 deposition. In models including all three biomarkers adjusted for age, sex, APOE E4 allele, AD polygenic risk score and cortical atrophy score, p-tau181 (0.93\u00b10.31, p\u200a&lt;\u200a0.01, R2\u200a=\u200a0.18) and GFAP (0.93\u00b10.41, p\u200a=\u200a0.03, R2\u200a=\u200a0.11), but not NFL (0.25\u00b10.51, p\u200a=\u200a0.62, R2\u200a=\u200a0.01), were associated with FLR-A\u03b2 deposition. Plasma p-tau181 was not associated with tau-PET burden. Conclusion: In cognitively unimpaired adults, elevated plasma p-tau181 is associated with future increased A\u03b2 deposition across multiple brain regions. Our results highlight the potential utility of p-tau181 as a blood-biomarker to screen for brain-amyloid deposition in cognitively healthy individuals in a community-setting.<\/jats:p>","DOI":"10.3233\/jad-215639","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T13:58:46Z","timestamp":1650981526000},"page":"1517-1526","source":"Crossref","is-referenced-by-count":32,"title":["Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults"],"prefix":"10.1177","volume":"87","author":[{"given":"Emer R.","family":"McGrath","sequence":"first","affiliation":[{"name":"HRB Clinical Research Facility, National University of Ireland Galway, Galway, Ireland"},{"name":"The Framingham Heart Study, Framingham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa S.","family":"Beiser","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Boston University School of Public Health, Boston, MA, USA"},{"name":"Boston University School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"O\u2019Donnell","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Boston University School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Yang","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Boston University School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptaparni","family":"Ghosh","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Boston University School of Medicine, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitzi M.","family":"Gonzales","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Glenn Biggs Institute for Alzheimer\u2019s & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayandra J.","family":"Himali","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Boston University School of Public Health, Boston, MA, USA"},{"name":"Boston University School of Medicine, Boston, MA, USA"},{"name":"Glenn Biggs Institute for Alzheimer\u2019s & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia L.","family":"Satizabal","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Glenn Biggs Institute for Alzheimer\u2019s & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Massachusetts General Hospital, the Gordon Center for Medical Imaging and the Athinoula A. Martinos Center for Biomedical Imaging, Boston, MA, USA"},{"name":"Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA"},{"name":"Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell P.","family":"Tracy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT, USA"},{"name":"Department of Biochemistry, Larner College of Medicine, University of Vermont, Burlington, VT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Seshadri","sequence":"additional","affiliation":[{"name":"The Framingham Heart Study, Framingham, MA, USA"},{"name":"Boston University School of Medicine, Boston, MA, USA"},{"name":"Glenn Biggs Institute for Alzheimer\u2019s & Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-215639_ref1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-215639_ref2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"26","author":"Karikari","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-215639_ref3","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-215639_ref4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer\u2019s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nat Med"},{"key":"10.3233\/JAD-215639_ref5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"10.3233\/JAD-215639_ref6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/brain\/awaa399","article-title":"Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum","volume":"144","author":"Moscoso","year":"2021","journal-title":"Brain"},{"key":"10.3233\/JAD-215639_ref7","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1038\/s41380-020-0838-x","article-title":"Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer\u2019s disease: A longitudinal cohort study","volume":"26","author":"O\u2019Connor","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.3233\/JAD-215639_ref8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","article-title":"Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations","volume":"1","author":"Cullen","year":"2021","journal-title":"Nat Aging"},{"key":"10.3233\/JAD-215639_ref9","doi-asserted-by":"crossref","first-page":"fcab136","DOI":"10.1093\/braincomms\/fcab136","article-title":"Association of plasma P-tau181 with memory decline in non-demented adults","volume":"3","author":"Therriault","year":"2021","journal-title":"Brain Commun"},{"key":"10.3233\/JAD-215639_ref10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","article-title":"Associations of longitudinal plasma p-tau181 and NfL with tau-PET, A\u03b2-PET and cognition","volume":"92","author":"Rauchmann","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-215639_ref11","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.mcn.2018.12.001","article-title":"Biomarkers for tau pathology","volume":"97","author":"Sch\u00f6ll","year":"2019","journal-title":"Mol Cell Neurosci"},{"key":"10.3233\/JAD-215639_ref12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/0091-7435(75)90037-7","article-title":"The Framingham Offspring Study. Design and preliminary data","volume":"4","author":"Feinleib","year":"1975","journal-title":"Prev Med"},{"key":"10.3233\/JAD-215639_ref13","first-page":"93","article-title":"Incidence of dementia over three decades in the Framingham Heart Study","volume":"375","author":"Satizabal","year":"2016","journal-title":"N Engl J Med"},{"key":"10.3233\/JAD-215639_ref14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ana.22333","article-title":"Amyloid-\u03b2 associated cortical thinning in clinically normal elderly","volume":"69","author":"Becker","year":"2011","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-215639_ref15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-170001","article-title":"Depressive symptoms and tau accumulation in the inferior temporal lobe and entorhinal cortex in cognitively normal older adults: A pilot study","volume":"59","author":"Gatchel","year":"2017","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-215639_ref16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1093\/brain\/awn016","article-title":"Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer\u2019s disease","volume":"131","author":"Ikonomovic","year":"2008","journal-title":"Brain"},{"key":"10.3233\/JAD-215639_ref17","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.neuroimage.2006.01.021","article-title":"An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest","volume":"31","author":"Desikan","year":"2006","journal-title":"Neuroimage"},{"key":"10.3233\/JAD-215639_ref18","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/jcbfm.2010.123","article-title":"The use of alternative forms of graphical analysis to balance bias and precision in PET images","volume":"31","author":"Logan","year":"2011","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-215639_ref19","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/sj.jcbfm.9600146","article-title":"Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B","volume":"25","author":"Price","year":"2005","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.3233\/JAD-215639_ref20","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jalz.2018.04.011","article-title":"PET staging of amyloidosis using striatum","volume":"14","author":"Hanseeuw","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-215639_ref21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jneumeth.2008.05.005","article-title":"Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer\u2019s disease with Pittsburgh Compound B","volume":"172","author":"Raji","year":"2008","journal-title":"J Neurosci Methods"},{"key":"10.3233\/JAD-215639_ref22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.21164","article-title":"Imaging of amyloid burden and distribution in cerebral amyloid angiopathy","volume":"62","author":"Johnson","year":"2007","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-215639_ref23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/JAD-210232","article-title":"Association of midlife depressive symptoms with regional amyloid-\u03b2 and tau in the Framingham Heart Study","volume":"82","author":"Gonzales","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-215639_ref24","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.bbadis.2011.11.005","article-title":"PET amyloid-beta imaging in preclinical Alzheimer\u2019s disease","volume":"1822","author":"Vlassenko","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-215639_ref25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.24546","article-title":"Tau positron emission tomographic imaging in aging and early Alzheimer disease","volume":"79","author":"Johnson","year":"2016","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-215639_ref26","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jamaneurol.2019.1424","article-title":"Association of amyloid and tau with cognition in preclinical Alzheimer disease: A longitudinal study","volume":"76","author":"Hanseeuw","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-215639_ref27","doi-asserted-by":"crossref","first-page":"eabc0655","DOI":"10.1126\/scitranslmed.abc0655","article-title":"The cortical origin and initial spread of medial temporal tauopathy in Alzheimer\u2019s disease assessed with positron emission tomography","volume":"13","author":"Sanchez","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.3233\/JAD-215639_ref28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41588-019-0358-2","article-title":"Genetic meta-analysis of diagnosed Alzheimer\u2019s disease identifies new risk loci and implicates A\u03b2, tau, immunity and lipid processing","volume":"51","author":"Kunkle","year":"2019","journal-title":"Nat Genet"},{"key":"10.3233\/JAD-215639_ref29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease: Progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.3233\/JAD-215639_ref30","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","article-title":"Tau kinetics in neurons and the human central nervous system","volume":"97","author":"Sato","year":"2018","journal-title":"Neuron"},{"key":"10.3233\/JAD-215639_ref31","doi-asserted-by":"crossref","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Sci Adv"},{"key":"10.3233\/JAD-215639_ref32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","author":"Preische","year":"2019","journal-title":"Nat Med"},{"key":"10.3233\/JAD-215639_ref33","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1212\/WNL.0000000000012513","article-title":"Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy","volume":"97","author":"Grothe","year":"2021","journal-title":"Neurology"},{"key":"10.3233\/JAD-215639_ref34","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","article-title":"Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia","volume":"91","author":"Heller","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-215639_ref35","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325085"},{"key":"10.3233\/JAD-215639_ref36","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1212\/WNL.0000000000003680","article-title":"Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder","volume":"88","author":"Hansson","year":"2017","journal-title":"Neurology"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-215639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:06:03Z","timestamp":1777370763000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-215639"}},"subtitle":[],"editor":[{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":36,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-215639","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]}}}